Recent Updates
Recently added Catalysts

Upcoming Catalyst

Drug Pipeline Intelligence

Clinical Trial Results

Inside Trades

Options Data

News Section

Hedge Funds

Ownership Trends

Competitive Position

Adverum Biotechnologies, Inc.

$4.36

+0.12 (+2.83%)

D 33Pipeline Score Overvalued Biotech · Clinical
Market Cap
96.26 M
EPS
-8.57
P/E Ratio
-
Value Trade
4.43 M
6.08 %
Week
2.11 %
1 Month
24.22 %
3 Month
54.61 %
6 Month
-96.81 %
5 Year
-98.26 %
All Time
Cash Data

  • Cash Position

    -

  • Monthly Burn

    -

  • Runway

    -

Overview
Volume
1.02 M
52 Week Range
1.78 - 6.07
% held by Insiders
33.78 %
% held by Institutions
58.54 %
Enterprise Value
159.14 M
Total Shares
20.98 M
Short %
2.5 %
Float Shares
17.46 M
Company Description
Founded:31-07-2014

locked

Upcoming Catalyst
Catalyst Drug/Treatment Stage Probability of Approval Description Drug Type Therapeutic Area Source
phase 3 data readout example
Ixo-vec (ixoberogene soroparvovec) Wet age-related macular degeneration (wet AMD)
Phase 3
—

Subscribe to access the data.

Gene Therapies
Ophthalmologic System
Ixo-vec (ixoberogene soroparvovec) Wet age-related macular degeneration (wet AMD)
Phase 3
—

Subscribe to access the data.

Gene Therapies
Ophthalmologic System
Ixo-vec (ixoberogene soroparvovec) Wet age-related macular degeneration (wet AMD)
Phase 3
—

Subscribe to access the data.

Gene Therapies
Ophthalmologic System
Unlock Upcoming Catalyst data
Unlock the full Catalyst Timeline
Past FDA Catalysts & PDUFA Decisions
Date Drug Catalyst Stage Outcome Reaction Event Move % Best Trade %
2024-12-31
Ixo-vec (ixoberogene)
Phase 2 data readout
Phase 2
—
–
–
–
2024-12-31
Ixo-vec (ixoberogene)
Phase 2 data readout
Phase 2
—
–
–
–
2024-12-31
Ixo-vec (ixoberogene)
Phase 2 data readout
Phase 2
—
–
–
–
Unlock 1 more historical catalysts
Drug Pipeline Intelligence
D33
Pipeline Score
$25M
Pipeline Value
Overvalued
Valuation Signal
3
Drugs Scored
0.3x
rNPV / MCap
Top 44%
Micro Cap
(rank 518 of 923)
Percentile Rank
Adverum Biotechnologies, Inc. faces pipeline headwinds (33/100), with $411M risk-adjusted pipeline value, led by ADVM-022 in Neovascular Age-related Macular Degeneration (Phase 2).
Showing 1 of 1 assets
DrugIndicationPhaseNCT IDPTRSrNPVStatusEnrollmentVelocityDesignCompletionML SignalLast Change
ADVM-022
Gene therapy		Neovascular Age-related Macular DegenerationPhase 2NCT0553697323% $246M ACTIVE NOT_RECRUITING 69 STALLED C (59) Aug 1, 2028 -LOW
May 26, 2026
Unlock Drug Pipeline Intelligence
Clinical Trial Results
Drug Name Indications Phase Date Trial Results Summary Title Source
ixoberogene soroparvovec
Fast TrackRMAT
wet age-related macular degeneration
Phase 2
2024-11-15

52-week LUNA phase 2 clinical data and 4-year OPTIC clinical data

Read More

Adverum Biotechnologies Announces Webcast to Report 52-Week LUNA Phase 2 Clinical Data and 4-Year OPTIC Clinical Data, and to Provide Key Pivotal Program Design Elements

Read More
ixoberogene soroparvovec
Fast TrackRMAT
wet age-related macular degeneration
Phase 2
2024-11-15

52-week LUNA phase 2 clinical data and 4-year OPTIC clinical data

Read More

Adverum Biotechnologies Announces Webcast to Report 52-Week LUNA Phase 2 Clinical Data and 4-Year OPTIC Clinical Data, and to Provide Key Pivotal Program Design Elements

Read More
ixoberogene soroparvovec
Fast TrackRMAT
wet age-related macular degeneration
Phase 2
2024-11-15

52-week LUNA phase 2 clinical data and 4-year OPTIC clinical data

Read More

Adverum Biotechnologies Announces Webcast to Report 52-Week LUNA Phase 2 Clinical Data and 4-Year OPTIC Clinical Data, and to Provide Key Pivotal Program Design Elements

Read More
Unlock Clinical Trial Results data
Inside Trades
TREND
CORPORATE INSIDERS BOUGHT SHARES WORTH 1.8M IN THE LAST 3 MONTHS
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Unlock Inside Trades data
Show Data
Hedge Funds
TREND
HEDGE FUNDS INCREASED HOLDINGS BY 200.0K SHARES IN THE LAST QUARTER
Shares Held
2040.00B1530.00B1020.00B510.00B0
Q3
2024
Q4
2024
Q1
2025
Q2
2025
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Fund Count
60%
Share Volume
25%
Conviction
15%
Hedge Funds invested in ADVM
HedgeFund Name
( 3 )
% of Portfolio Current MV
-
Shares Owned
-
Activity
Avg Price $0

Example Capital Management

2.5 %
15.00 M
250.00 K

Example Capital Management

2.5 %
15.00 M
250.00 K

Example Capital Management

2.5 %
15.00 M
250.00 K
Unlock Hedge Funds table data
ADVM Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
ExpirationVolumeOpen InterestImplied Volatility CallsImplied Volatility Puts
CallsPutsPut-Call RatioCallsPutsPut-Call RatioIVOiWaIvVWaIvIVOiWaIvVWaIv
Unlock Option Chain Statistics data
Option Chain
CallsStrikePuts
Last PriceVolumeOpen InterestLast PriceVolumeOpen Interest
No data available
Unlock Option Chain data
Unlock Options Chart data
Open interest
0 600K 1.2M 1.8M Avg OI 1.00 M Open Interest
0 1 2 3 1.1 Put-Call Ratio
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
0 450K 900K 1.4M Avg OV 750.00 K Option Volume
0 1 2 3 0.95 Put-Call Ratio
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
Competitive Position
How ADVM ranks across every disease it competes in
Competitive Position is a premium feature
See how ADVM ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial